DEC.

30

Best Wishes 2017

BIOTEM's Team wishes you a Successful and Happy New Year 2017!

DEC.

01

ISO 13485:2012 Certification

In addition to its ISO 9001:2008 certification (Quality Management System), BIOTEM is also certified ISO 13485:2012 for its activities in the development, manufacturing and marketing of immunoassays for in vitro diagnostic use.

 

Learn more here

NOV.

01

Ultimate Humanization®: Towards a New Generation of Therapeutic Antibodies

LaBiotech has published an article about BIOTEM's innovative services in the field of therapeutic antibody

SEP.

12

Food Allergens: BIOTEM launches rapid detection strips

BIOTEM launches rapid tests under the brand Disp&FLOW® for the detection of food allergens

JUL.

09

BIOTEM & FISHGUARD Project

BIOTEM proposes its know-how and expertise for the FISHGUARD Project whose objective is to develop rapid tests to detect specific viruses in fishes.

BIOTEM - Fishguard Press Release : Format PDF, 0,2 Mo

JUL.

02

EnviGuard: High Affinity Antibodies

Thanks to its expertise on difficult hapten targets, BIOTEM has implemented several chemical strategies for the preparation of immunogens such as structural analysis, functionalization and conjugation.  

In addition, BIOTEM brought its 35-year know-how to the antibody development by proposing its innovative technologies such as the Phage Display Platform.

 

More information: http://www.enviguard.net/index.php/news/item/13-advances-enviguard-chemicals-module

JAN.

12

Doxycycline Rapid Strip

BIOTEM announces the commercial launch of its test Doxycycline Rapid Strip developed in collaboration with an International petroleum group. The test allows efficacy gaining in Malaria chemoprophylaxis compliance verification by the direct detection of Doxycycline in urine. This innovative tool offers many advantages over classical analytical methods by being fast, simple and cost effective.

BIOTEM - Press Release : Format PDF, 0,38 Mo

MAY.

19

EnviGuard: The European Collaborative Project to Protect Marine Environment

The objective of the EnviGuard project is to develop an in situ device for the currently hard to measure man-made chemical contaminants and biohazards in marine environment. This device will be used as an early warning system to assess the good environmental status of the sea or aquacultures in compliance with the MSFD (Marine Strategy Framework Directive).

This collaborative project has received funding from the European Union’s Seventh Framework Programme (FP7).

 

BIOTEM will contribute to the EnviGuard project by generating high affinity and specific monoclonal antibodies against toxins and man-made pollutants.

APR.

09

Anti-GRA Monoclonal Antibodies

Toxoplasma gondii is the pathogen responsible for toxoplasmosis. GRA proteins contains in dense granules are important for infection of host cell.

 

BIOTEM is the exclusive producer of 3 monoclonal antibodies with a strong specificity for GRA 1, GRA 2 and GRA 5 Toxoplasma gondii proteins.

  • Anti-GRA1 - clone TG 17.43 - ref# BIO.018.4
  • Anti-GRA2 - clone TG 17.179 - ref# BIO.018.5
  • Anti-GRA5 - clone TG 17.113 - ref# BIO.018.6

 

BIOTEM - BIO.018.4 - Anti-GRA1 : Format PDF, 0,45 Mo
BIOTEM - BIO.018.5 - Anti-GRA2 : Format PDF, 0,46 Mo
BIOTEM - BIO.018.6 - Anti-GRA5 : Format PDF, 0,46 Mo

MAR.

19

New laboratories
BIOTEM has moved into its new headquarters at the beginning of the year.
Putting emphasis on space and light, this new structure includes a set of ultra modern offices and laboratories with a surface area of 2 000 m².
The company increases thereby its production capacity in accordance with its development and growth perspective.

MAY.

01

BIOTEM joins OneNucleus

Recently established in Cambridge (within the prestigious Silicon Fen), BIOTEM actively pursues its international development and joins OneNucleus in April 2011.
Based in London and Cambridge, this organisation federates a network over 500 members at the heart of the first European cluster dedicated to life sciences.

SEP.

01

BIOTEM is celebrating its 30 anniversary !

Founded in 1980, BIOTEM is the first French CMO to have proposed the production of customised monoclonal antibodies.
To mark the 30th anniversary of the company, we would like to thank you all our partners and customers for their trust and contribution to BIOTEM's success.

Today, BIOTEM actively continues its development and confirms its position as a leader in the field of monoclonal antibodies.

* Contrat Manufacturing Organisation

MAY.

01

APR.

01

R.A.D : Rapid Antibody Development

This exclusive method allows the fast development of hybridomas in less than a month (immunisation, fusion and screening included).

OCT.

01

ISO9001:2000

BIOTEM complies with the ISO 9001:2000 quality standards